Nanotechnology-based drug-delivery research shows early promise
Published on Friday 12 March 2010 - 10:04 - http://www.nanowerk.com/Northeastern University pharmaceutical sciences professor Mansoor Amiji is leading interdisciplinary research into nanotechnology-based methods of drug delivery that could provide breakthroughs in...
Medivation Class Action Has Questionable Roots
Published on Wednesday 10 March 2010 - 18:40 - http://www.bloggingstocks.com/Filed under: Management, Law, Pfizer (PFE)As class action lawsuits go, I have never encountered one any more questionable than the recent complaint issued against Medivation Inc. (MDVN), via the...
Brooke Shields: Mom’s Alzheimer’s Affects Daughters
Published on Monday 08 March 2010 - 22:00 - http://celebrity-babies.com/Courtesy Ladies Home Journal for use on CBB''''A childhood spent acting and modeling is an experience Brooke Shields knows all too well. It is, however, one that her two daughters will not be...
Bacterial product isolated in soil from Easter Island rescues learning, memory in Alzheimer's mouse model
Published on Monday 08 March 2010 - 20:00 - http://www.sciencedaily.com/A new study offers the first evidence that the drug rapamycin -- a bacterial product first isolated in soil from Easter Island -- is able to reverse Alzheimer's disease-like deficits in an animal...
Nursing home antipsychotic use under fire
Published on Monday 08 March 2010 - 16:45 - http://www.fiercepharma.com/Massachusetts joins the cadre of states spending funds on antipsychotics for nursing home patients who probably shouldn't be given the drugs at all, the Boston Globe reports. According to data...
Medivation, Pfizer Disappointed Over Drug Failure - Biotech's Latest Mishaps
Published on Monday 08 March 2010 - 10:22 - http://seekingalpha.com/The Burrill Report submits: Pfizer (PFE) and Medivation (MDVN) said dimebon, their experimental drug to treat Alzheimer s disease, failed in two late-stage clinical trials. Medivation s stock,...
After Dimebon failure, where next for Alzheimer’s?
Published on Monday 08 March 2010 - 01:00 - http://www.pharmatimes.com/The disappointing failure in late-stage trials of Pfizer and Medivation's Dimebon last week is a major setback, but the plethora of other drugs in development are cause for optimism for Alzheimer’s...
Medivation's Next Moves
Published on Sunday 07 March 2010 - 18:00 - http://www.thestreet.com/From the Best of TSC TV: Shares of Medivation are down almost 70% after a failed Alzheimer drug study. Adam Feuerstein looks at what's next for the company and partner Pfizer. Original air date:...
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer's Disease Clinical Development Program
Published on Friday 05 March 2010 - 12:00 - http://www.medicalnewstoday.com/Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer's disease (AD)....
The End of the Biotech Rally
Published on Thursday 04 March 2010 - 22:39 - http://seekingalpha.com/R. Scott Raynovich submits:The risks in the biotech market were evident on Wednesday as Medivation (MDVN) crashed after releasing disappointing Phase III results for its Alzheimer drug, known as...
